Dr. Goodenow has served at executive and senior management levels in multinational pharmaceutical and biotechnology companies, with roles in research and development, business development, and commercialization. He has a strong licensing track record, including global and regional transactions. With over 28 years’ industry experience, Dr. Goodenow served most recently as Chief Business Officer at Syndax Pharmaceuticals, where he led commercial development efforts for the company’s epigenetic platform in oncology.
Prior to this, he was Vice President of Corporate Development for Inovio Biomedical and held various senior positions within Rhône-Poulenc Rorer, Aventis and Baxter Healthcare. Dr. Goodenow received a PhD in Biophysics from Stanford University Medical School and holds an AB in Biochemistry from the University of California at Berkeley. He was an American Cancer Society Fellow in the Division of Biology at CALTECH.